Document is current
Any future updates will be listed below
-
Authors
Gotfried, Mark H. https://orcid.org/0000-0001-7279-8101
Auerbach, Sanford H. https://orcid.org/0000-0003-2962-6405
Dang-Vu, Thien Thanh https://orcid.org/0000-0002-7235-2721
Mishima, Kazuo https://orcid.org/0000-0003-1182-1181
Kumar, Dinesh https://orcid.org/0000-0001-5880-4237
Moline, Margaret https://orcid.org/0000-0003-0807-2167
Malhotra, Manoj https://orcid.org/0000-0002-4315-8284
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02783729 at ClinicalTrials.govnct02583451 at ClinicalTrials.govDocuments that mention this clinical trial
FLUID study: study protocol for an open-label, single-centre pilot study to investigate the efFect of Lemborexant on sleep management in Japanese sUbjects aged 50 years and older with Insomnia Disorder
https://doi.org/10.1136/bmjopen-2021-054885
Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials
https://doi.org/10.1007/s40266-024-01135-8
nct03008447 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials
https://doi.org/10.1007/s40266-024-01135-8
Documents that mention this clinical trial
Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials
https://doi.org/10.1007/s40266-024-01135-8
-
Funding
Funding for this research was provided by:
Eisai Incorporated
- License Information
-
More Information
Article History
Accepted: 15 July 2024
First Online: 9 August 2024
Declarations
:
: This work was supported by Eisai Inc., which is the manufacturer/licensee of lemborexant. Eisai was involved in the study design, data collection, data analysis, and preparation of the manuscript.
: Dr. Gotfried has received research support and/or speaker fees from Eisai Inc., Idorsia, Jazz Pharmaceuticals, and Merck. Dr. Auerbach declares he has no conflicts of interest. Dr. Dang-Vu has been a consultant and/or speaker for and/or has received research support from Eisai Inc., Jazz Pharmaceuticals, and Paladin Labs. Dr. Mishima has been a consultant and/or speaker for and/or has received research support from Eisai Co., Ltd., MSD, Nobelpharma, and Takeda Pharmaceutical Limited. Drs Kumar and Moline are employees of Eisai Inc. Dr. Malhotra is a former employee of Eisai Inc.
: The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.
: The study protocols were approved by relevant institutional review boards and independent ethics committees. The studies adhered to Good Clinical Practice guidelines, the Declaration of Helsinki and local regulations.
: All study participants provided written informed consent prior to participation.
: Not applicable.
: Not applicable.
: Study concept and design: Margaret Moline. Acquisition of subjects and/or data: Mark H. Gotfried. Analysis and interpretation of data: all authors. Preparation of manuscript: all authors. All authors have read and approved the final submitted manuscript and agree to be held accountable for the work.
